Gyrolab®: Case studies in assay development and validation

Thursday 29 April 2021
07:00 [PST] 10:00 [EST] 15:00 [BST]
Alternative time zones

REGISTER NOW

Gyrolab provides a highly automated platform that optimizes immunoassays for use at the nanoliter-scale, enabling testing when sample volume is limited. As part of this webinar, we will talk about BioAgilytix’s experience with this platform as it relates to assay development and validation in the context of both regulated and non-regulated support.

Topics may include:

  • Overall experience with the platform
  • Different matrices and species
  • Duplicate vs. singlets
  • Assay troubleshooting

Following the presentation, we will have a live roundtable with our experts to take your questions about this exciting and useful platform.

What will you learn?

Experience with:

  • Different matrices and species
  • Troubleshooting tips
  • Regulated vs. non-regulated support
  • Logistics issues (sample volume, CDs, buffers)

Who may this interest?

  • Bioanalytical scientists
  • Biomarker scientists
  • Those working in non-clinical development (pharmacology and toxicology)
Jim McNally
Jim McNally
Chief Scientific Officer
BioAgilytix (MA, USA)

Dr McNally has an extensive background in bioanalytical assay development and program leadership spanning 20+ years working in the pharmaceutical and biotechnology industry. Prior to joining BioAgilytix, Dr McNally was Executive Director at CRISPR Therapeutics (MA, USA), where he led a team of scientists to develop assays to support development of gene-edited therapeutic candidates. He has also previously held roles at Genzyme (MA, USA), Pfizer (MA, USA), EMD Serono (MA, USA) and Shire (MA, USA), which have given him broad experience in the development of large molecule, gene therapy and cell therapy biotherapeutics. He has a special interest in the immunogenicity of biotherapeutics and leads an industry-wide working group on this topic.

Carla Mejia
Carla Mejia
Manager II, Operations
BioAgilytix (NC, USA)

Carla has over 13 years of experience in the pharmaceutical industry, including over 8 years at BioAgilytix. Before joining the BAL team, Carla worked for GSK (NC, USA) and Grifols (NC, USA). She has over a decade of experience working on development, validation and sample analysis of immunogenicity ELISA and PK assays. She has extensive experience developing assays for a variety of matrices for both animal and human studies. At BioAgilytix, Carla currently manages an FTE model team that develops, validates and executes sample analysis for PK, ADA and biomarker assays on multiple platforms including MSD, ELISA and Gyros platforms. She earned her Bachelor of Science in Biochemistry from North Carolina State University (NC, USA).

In association with